source
- Novo abandons $285 million partnership with Ascendis for monthly GLP-1 obesity drugNovo Nordisk, which recently rebranded, has terminated a licensing agreement with Ascendis Pharma that was originally valued at up to $285 million. The collaboration, signed in November 2024, was…
- Novartis shareholder urges board overhaul after costly Avidity acquisition setbacksNovartis investor David Samra, managing director at Artisan Partners, told Reuters that the company’s board should be reshaped to improve oversight of its dealmaking activities. He said the board n…